夜间酸突破的临床意义和治疗措施被引量：9

导出

摘要夜间酸突破现象(NAB)在应用质子泵抑制剂的人群中有很高的发生率,其发生机制复杂,与反流性食管炎、Barrett食管等酸相关性疾病有密切的联系。控制夜间酸突破是成功治疗上消化道酸相关性疾病的重要挑战,目前对其治疗主要以每日2次PPI联合睡前加服H2受体拮抗剂(H2RA)的方案为主,但疗效短暂。近年来对于NAB现象已有一定的认识,但仍处于探索阶段,还需要更多大样本的临床研究以寻求更好的治疗措施。

作者周鸿吕宾

机构地区浙江中医药大学附属第一医院消化科

出处《国际消化病杂志》 CAS 2010年第5期263-266,共4页 International Journal of Digestive Diseases

关键词夜间酸突破临床意义发生机制治疗措施

分类号 R571 [医药卫生—消化系统]

引文网络
相关文献

参考文献25

1Pfefferkorm MD,Croffie JM,Gupta SK,et al.Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors.J Pediatr Gastroenterol Nutr,2006,42:160-165.
2Katsube T,Adachi K,Kawamura A,et al.Helieohacter pylori infetion influences nocturnal gastric acid breakthrough.Aliment Pharmacol Ther,2000,14:1049-1056.
3Katz PO,Andderson C,Khoury R,et al.Gastro-esophageal reflux associated with nocturnal gastric acid hreakthrough on proton pump inhibitors.Aliment Pharmacol Ther,1998,12,1231-1234.
4Xue S,Katz PO,Banerjee P,et al.Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.Aliment Pharmacol Ther,2001,15,1351-1356.
5Orr WC,Harnish MJ.The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.Aliment Pharmacol Ther,2003,17= 1553-1558.
6Ours TM,Fackler WT,Richter JE,et al.Nocturnal acid breakthrough:clinical significance and correlation with esophageal acid exposure.Am J Gastroenterol,2003,98:545-550.
7Ghoshal UC,Chourasia D,Tripathi S,et al.Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough.,a study using 24 h dual-channel pH-metry.Scand J Gastroenterol,2008,43:654-661.
8Weigt J,Kandulski A,Busch F,et al.Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.Dig Dis,2009,27:68-73.
9Kolesnikova If,Beliaeva GS,Leont'eva VA.Clinical significance of "night acid burst" phenomenon in patients with duodenal ulcer.Eksp Kiln Gastroenterol,2008,4,9-11.
10Furuta T,Shirai N,Sugimoto M,et al.Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Drug Metab Pharmacokinet,2005,20:153-167.

二级参考文献15

1Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic,endoscopic, and histological evaluations. Gut, 1990; 31(9): 968-972.
2Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol, 1998; 93(5): 763-767.
3Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.Aliment Pharmacol Ther, 1998; 12(12): 1231-1234.
4Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology, 1999; 117(2): 327-335.
5Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.J Clin Invest, 1996; 98(9): 2120-2128.
6Peters FT, Ganesh S, Kuipers E J, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut, 1999; 45(4): 489-494.
7Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnalgastric acid breakthrough on omeprazole: a controlled study innormal subjects, Gastroenterology, 1998; 115(6): 1335-1339.
8Katsube T, Adachi K, Kawamura A, et al. Helicobacter pyloriinfection influences nocturnal gastric acid breakthrough.Aliment Pharmacol Ther ,2000;14(8):1049-1056.
9Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C 19. Clin Pharmacol Ther, 2001 ;70(5): 484-492.
10Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology,2002; 122(3): 625-632.